ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has single-digit 5-year survival rates at <7%. There is a dire need to improve pre-malignant detection methods and identify new therapeutic targets for abrogating PDAC progression. To this end, we mined our previously published pseudopodium-enriched (PDE) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharibi, Armen, La Kim, Sa, Molnar, Justin, Brambilla, Daniel, Adamian, Yvess, Hoover, Malachia, Hong, Julie, Lin, Joy, Wolfenden, Laurelin, Kelber, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577248/
https://www.ncbi.nlm.nih.gov/pubmed/28855593
http://dx.doi.org/10.1038/s41598-017-09946-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577248/
https://www.ncbi.nlm.nih.gov/pubmed/28855593
http://dx.doi.org/10.1038/s41598-017-09946-z

Ejemplares similares